A Tucker man with Down syndrome is the only participant in a Vanderbilt clinical trial testing a potential treatment to lower ...

A growing body of evidence suggests that a single gene, APOE, may play a far more dominant role in Alzheimer’s disease than ...

On 18 March, Eisai presented four-year data from its OLE period of its Phase III CLARITY-AD trial of Leqembi to treat early ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering ...

The research found that the complex is more prevalent in mice with Alzheimer's than those without. The team also discovered a ...

Genetic switches near the FTO locus may enable hibernators’ extreme metabolic resilience and could inspire future treatments ...

Novel and potent catalytic approach that directly clears amyloid on the inside of neurons as well as reduces amyloid plaques with the potential to be superior to monoclonal antibodies and restore ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic ...

Hormone therapy is widely used to treat menopausal symptoms such as hot flashes and night sweats. But scientists have long ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

Researchers found a link between 29 infections and diseases, including cystitis and Parkinson's, and a higher risk of ...